🇺🇸 FDA
Pipeline program

ALX-0061

ALX0061-C204

Phase 2 mab completed

Quick answer

ALX-0061 for Lupus Erythematosus, Systemic is a Phase 2 program (mab) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pasteur
Indication
Lupus Erythematosus, Systemic
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials